In addition, directly targeting MCL-1 with small molecular MCL-1 inhibitors exhibits potent efficacy such as S63845, AZD5991, and AMG176, sensitizing CRC cells to treatment of the targeted drug regorafenib by virtue of restoring apoptotic response (61). Here, MCL1 is linked to colorectal carcinoma.